In section Releases

Consumer365 Names Happy Head Top Choice for Personalized Hair Loss Care

Consumer365 has designated Happy Head as the 2026 leader in personalized minoxidil treatments for women, highlighting a model that moves away from fixed-dose formulas toward dermatologist-supervised, compounded care. The selection focuses on the provider's ability to tailor prescriptions based on age, medical history, and specific hair-loss patterns.

Consumer365 Names Happy Head Top Choice for Personalized Hair Loss Care

The report emphasizes that hair restoration requires more than a one-size-fits-all approach. By leveraging a telehealth platform, Happy Head allows patients to undergo remote assessments by board-certified dermatologists who then create custom-compounded medications. These range from topical solutions containing up to 8% minoxidil to oral regimens that may incorporate dutasteride or vitamin D3. Because these medications are compounded per order, they are not FDA-approved in the traditional sense and are often prescribed off-label based on clinical judgment.

Treatment pathways are categorized by age, with distinct protocols for women over 50 versus those under 50. For instance, younger patients may be prescribed oral spironolactone or minoxidil paired with retinoic acid, while older cohorts might receive more aggressive combinations involving dutasteride. Despite these categories, the company stresses that no prescription is automatic; each treatment plan depends entirely on a patient's health profile, pregnancy status, and existing medication list. Founded in 2021 by dermatologists Dr. Ben Behnam and Dr. Sean Behnam, the service aims to bridge the gap between clinical hair restoration and home-based convenience. Patients generally begin seeing results within three to six months, though outcomes remain highly individual.

Share:on TelegramXFacebook

Subscribe to our newsletter

Once a week — the best stories from our editors, no ads or push notifications. Delivered Sunday morning.

Comments (0)

Leave a comment

No comments yet. Be the first!